Summary:
Genetically engineered T cells have been successful in treating blood cancers but have yielded limited benefits in solid tumors. Scientists have explored different combination strategies to overcome the problem but faced disappointing efficacy or unacceptable side effects.
Article written by Angus Liu
30|11|2020
Source:
Fierce Biotech